Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients

Table 1 Baseline characteristics and clinical outcome of patients treated with entecavir for hepatitis B virus reactivation

Parameter	Patient No.
	1	2	3	4
Age (yr)	66	57	51	78
Sex	M	F	F	F
Disease entity	AML	FL	AML	B-CLL
HBV serology prior to chemotherapy	ND	ND	anti-HBc pos., anti-HBs pos., HBs-Ag neg.	ND
Chemotherapy/treatment	HSCT	Prednisone	HSCT	Bendamustine
Peak ALT (IU/L)	870	3290	2592	711
Peak bilirubin level (mg/dL)	20	10	4.1	1
INR	1.4	1.0	1.0	1.0
Time of clinical disease presentation	9 mo after HSCT	During prednisone treatment	27 mo after HSCT; 8 mo after cessation of LAM prophylaxis	During current chemotherapy
HBV-DNA (IU/mL) at time of HBV reaction	8.06 × 107	5.65 × 105	1.00 × 105	4.50 × 107
HBeAg at time of reactivation	Positive	Negative	Positive	Positive
HBeAg loss	Yes	NA	Yes	Yes
HBsAg loss	Yes	Yes	Yes	No
Withdrawal of antiviral treatment	No	Yes	Yes	No
Anti-HBs (IU/L)	42	361	277	-
Clinical outcome	Alive	Alive	Alive	Malignancy related death

AML: Acute myeloid leukemia; B-CLL: B-cell chronic lymphocytic leukemia; FL: Follicular lymphoma; LAM: Lamivudine; ND: Not determined; HBV: Hepatitis B virus; HSCT: Hematopoietic stem cell transplantation; NA: Not applicable; INR: International normalized ratio; HBeAg: Hepatitis B e antigen; HBsAg: Hepatitis B surface antigen; ALT: Alanine aminotransferase.